Abstract
This study aimed to analyze the independent risk factors for predicting preeclampsia severity and explore its underlying mechanism. Clinical data of patients with preeclampsia were collected from the Medical Information Mart for Intensive Care (MIMIC)-IV database. Univariate and multivariate analyses were employed to assess the significant factors associated with preeclampsia severity. Based on inclusion and exclusion criteria, 731 participants were enrolled: 381 with severe preeclampsia and 350 with mild-to-moderate preeclampsia. Age and uric acid were identified as independent predictors for preeclampsia severity. Furthermore, mediation analysis showed that uric acid acts as a mediator in the relationship between white blood cell (WBC) counts and preeclampsia severity, suggesting that systemic inflammation might drive disease progression through oxidative stress pathways.
Introduction
Preeclampsia—characterized by high blood pressure and organ damage after 20 weeks of pregnancy—remains a leading cause of maternal and fetal mortality. While the medical community understands that it involves a "two-stage" process involving poor placental blood flow followed by a systemic inflammatory response, the specific pathways that turn a mild case into a life-threatening severe one are not fully understood. Clinicians have long noted correlations between elevated white blood cells (WBCs), high uric acid, and disease severity, but it wasn't clear if these were independent symptoms or part of a single functional chain. This paper seeks to map that regulatory path to improve early diagnosis and intervention.
Methods and Data
The researchers conducted a retrospective analysis using the Medical Information Mart for Intensive Care (MIMIC)-IV database. This massive, publicly available de-identified dataset contains clinical information from patients admitted to the ICU at Beth Israel Deaconess Medical Center. Using an ICU-specific database allowed the authors to focus on high-acuity cases where laboratory monitoring is most frequent.
Statistical modeling involved univariate and multivariate logistic regression to isolate independent risk factors. Crucially, a mediation analysis was performed to test the hypothesis of a causal flow: does Variable A (WBC) affect Variable C (Severity) through Variable B (Uric Acid)?
Key Results and Insights
The study identified several clinical markers significantly associated with severity, including WBC, platelets, creatinine, albumin, and liver enzymes. However, multivariate models narrowed these down to two independent predictors: age and uric acid.
The Role of Uric Acid as a Mediator
The most significant finding was the confirmation that uric acid isn't just a marker of kidney stress in preeclampsia; it is a functional bridge. The mediation analysis confirmed a significant indirect effect (p=0.008) of WBC on preeclampsia severity through uric acid.
The authors propose a biological mechanism: infiltrating WBCs release Reactive Oxygen Species (ROS) via the "respiratory burst" process. This oxidative stress alters uric acid production, which in turn induces endothelial dysfunction (damage to the lining of blood vessels), aggravating the disease severity.
Statistical Findings
- Severity Predictors: Uric acid was a significant independent predictor of severity (Odds Ratio [OR] 1.279, p=0.049).
- WBC-Uric Acid Link: WBC counts were independently correlated with uric acid levels (OR 1.056, p=0.041).
- Clinical Outcomes: Patients in the severe group had significantly higher WBC counts (11.00 vs 10.38 K/uL) and uric acid levels (5.54 vs 5.33 mg/dL), as well as significantly longer hospital stays (6.76 vs 5.94 days).
Discussion and Limitations
While this study provides novel insight into preventing preeclampsia development, it has limitations. Because the data comes from an ICU database, the findings primarily apply to critical cases and might not generalize to all pregnant women. Additionally, the retrospective nature of the study suggests a pathway but cannot definitively prove causation. Future prospective clinical trials are needed to validate these findings and define specific uric acid thresholds for clinical intervention.
Summary updated